Table 1. Baseline patient and disease... | American Society of Hematology

Table 1.

Baseline patient and disease characteristics with univariate analysis

Variable	N	%	PFS			OS
Variable	N	%	HR	95% CI	P	HR	95% CI	P
Age, yr
<40	233	36	Ref
40-59	257	40	1.70	1.25-2.32	<.001	2.14	1.51-3.04	<.001
60+	151	24	2.14	1.52-3.00	<.001	2.61	1.78-3.82	<.001
Sex
Male	485	76	Ref
Female	156	24	1.06	0.79-1.41	0.70	0.92	0.67-1.27	0.61
HIV
Negative	487	76	Ref
Positive	142	22	1.13	0.84-1.52	0.42	1.13	0.82-1.55	0.46
NA	12	2
ECOG
0-1	453	71	Ref
2-4	144	22	2.24	1.7-2.96	<.001	2.58	1.92-3.47	<.001
NA	44	7
MYC rearrangement
No	65	10	Ref
Yes	576	90	1.26	0.80-1.97	0.31	1.25	0.77-2.04	0.36
Advanced stage
No	131	20	Ref
Yes	500	78	2.29	1.54-3.39	<.001	2.44	1.57-3.8	<.001
NA	10	2
B symptoms
No	330	51	Ref
Yes	304	47	1.19	0.92-1.54	0.18	1.14	0.86-1.5	0.37
NA	7	1
Greater than 1 EN site*
No	353	55	Ref
Yes	275	43	1.24	0.96-1.6	0.09	1.29	0.98-1.7	0.07
NA	13	2
Marrow involved
No	392	61	Ref
Yes	222	35	1.68	1.29-2.17	<.001	1.84	1.39-2.45	<.001
NA	27	4
CNS involved
No	521	81	Ref,
Yes	120	19	2.02	1.52-2.67	<.001	2.18	1.61-2.94	<.001
Hgb < 11.5 g/dL
Normal	345	54	Ref
Low	264	51	1.73	1.33-2.25	<.001	1.77	1.33-2.36	<.001
NA	32	5
Albumin < 3.5 g/dL
Normal	329	51	Ref
Low	254	40	1.56	1.20-2.04	.001	1.72	1.28-2.28	<.001
NA	58	9
LDH > 3× ULN
No	351	55	Ref
Yes	247	39	2.27	1.73-2.96	<.001	2.20	1.65-2.94	<.001
NA	43	7

Variable	N	%	PFS			OS
Variable	N	%	HR	95% CI	P	HR	95% CI	P
Age, yr
<40	233	36	Ref
40-59	257	40	1.70	1.25-2.32	<.001	2.14	1.51-3.04	<.001
60+	151	24	2.14	1.52-3.00	<.001	2.61	1.78-3.82	<.001
Sex
Male	485	76	Ref
Female	156	24	1.06	0.79-1.41	0.70	0.92	0.67-1.27	0.61
HIV
Negative	487	76	Ref
Positive	142	22	1.13	0.84-1.52	0.42	1.13	0.82-1.55	0.46
NA	12	2
ECOG
0-1	453	71	Ref
2-4	144	22	2.24	1.7-2.96	<.001	2.58	1.92-3.47	<.001
NA	44	7
MYC rearrangement
No	65	10	Ref
Yes	576	90	1.26	0.80-1.97	0.31	1.25	0.77-2.04	0.36
Advanced stage
No	131	20	Ref
Yes	500	78	2.29	1.54-3.39	<.001	2.44	1.57-3.8	<.001
NA	10	2
B symptoms
No	330	51	Ref
Yes	304	47	1.19	0.92-1.54	0.18	1.14	0.86-1.5	0.37
NA	7	1
Greater than 1 EN site*
No	353	55	Ref
Yes	275	43	1.24	0.96-1.6	0.09	1.29	0.98-1.7	0.07
NA	13	2
Marrow involved
No	392	61	Ref
Yes	222	35	1.68	1.29-2.17	<.001	1.84	1.39-2.45	<.001
NA	27	4
CNS involved
No	521	81	Ref,
Yes	120	19	2.02	1.52-2.67	<.001	2.18	1.61-2.94	<.001
Hgb < 11.5 g/dL
Normal	345	54	Ref
Low	264	51	1.73	1.33-2.25	<.001	1.77	1.33-2.36	<.001
NA	32	5
Albumin < 3.5 g/dL
Normal	329	51	Ref
Low	254	40	1.56	1.20-2.04	.001	1.72	1.28-2.28	<.001
NA	58	9
LDH > 3× ULN
No	351	55	Ref
Yes	247	39	2.27	1.73-2.96	<.001	2.20	1.65-2.94	<.001
NA	43	7

EN, extranodal; Hgb, hemoglobin; NA, not available; Ref, reference.

Most common non–bone marrow EN sites (>5% of patients): gastrointestinal 37% (n = 234); CNS 19% (n = 120); lung/pleura 16% (n = 105); bone 16% (n = 102); liver 14% (n = 88); kidney/adrenal 8% (n = 54); gonadal 7% (n = 38).

View Large

This Feature Is Available To Subscribers Only